drugset
drugset / Trial / NCT03379441

Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

NCT03379441 ↗

Phase 2 Unknown 126 enrolled University of Turin, Italy
RandomizedParallel-groupDouble-blindTreatment

Summary

Maintainance therapy in patients with unresectable stage III, NSCLC Stage IIIA-B, unresectable, NSCLC, treated with definitive Chemo-Radiotherapy

Timeline

Start
2018-01-01
Primary completion
2023-01-01
Completion
2023-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

non-small cell lung carcinoma